Skip to content

AIM round-up: Cloudcoco, Sareum Holdings, Remote Monitored Systems


It was another lacklustre day for the AIM Index, spending the session in negative territory although losses were slim, reaching the bell less than six points lower at 1252.05

  • Cloudcoco +16%
  • Sareum Holdings +14%
  • Clinigen Group -26%
  • Plutus Power -24%
  • Remote Monitored Systems -20%

IT solutions provider Cloudcoco LON:CLCO topped the board today, although gains were a modest 16%. The release of interim results triggered gains after revenues moved higher and losses were curtailed. The company also advised that two major contracts had been extended on a multi-year basis, although gains also need to be considered in the light of this being a sub £10m market cap company and the fact the gains were at least in part absorbed by the spread.

Sareum Holdings LON:SAR also fared comparatively well, adding 15% today. The stock jumped early last week on the back of that investment news, has been making steady gains since and has come back onto our radar today by virtue of little activity elsewhere. The protracted state of these gains is notable.

Clinigen Group [LON:CLIN] slipped 26% today following an update to the market on the negative impact COVID-19 has had on trade. As we have seen with others in healthcare, some treatments have been pushed back in order for the industry to focus on the global health pandemic. The downgrade in revenues may be seen as temporary but the market has been less forgiving.

Plutus Power [LON:PPG] slipped 24% ahead of what seems like an inevitable suspension for the stock looming. The company advised of its rule 15 status back in early December and with this still a cash shell, tomorrow will see the six month period having elapsed. There was some demand for the stock but the hulking wide spread tells its own story.

A feast of regulars vying for the notable mention today, but Remote Monitored Systems [LON:RMS] perhaps has to take the title. This morning’s publication of full year results painted a less than impressive picture for the business, with the anti-viral mask project struggling against increasing vaccine roll outs. There are however sales opportunities here and the company also noted that the technology can be used in other PPE items. The stock however reached the bell down 20% at fresh lows for the year. However, that’s still around six times higher than the lows seen just over a year ago – long term investors still have something to cheer.

Looking for great investing ideas? Sign up to our free newsletter.

Join us on WhatsApp

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets
Back To Top